UP45

UP45 is a biotechnology company focused on the discovery and development of small molecule therapeutics targeting the ubiquitin-proteasome system, specifically deubiquitinating enzymes (DUBs). The company leverages a proprietary platform to identify and optimize selective inhibitors of DUBs, which play critical roles in protein homeostasis and cellular signaling. By modulating these enzymes, UP45 aims to address high unmet medical needs in oncology and neurodegeneration. The company's approach involves targeting specific DUBs that are dysregulated in disease states to restore normal cellular function or induce the degradation of pathogenic proteins. UP45 is currently in the pre-clinical stage, advancing a pipeline of novel drug candidates toward clinical development.